| P50 | author | Romain Boidot | Q88041644 |
| | Céline Didelot | Q55300030 |
| | Nadine Millot | Q57617373 |
| | Julien Boudon | Q59915751 |
| P2093 | author name string | Etienne Martin | |
| | Sandy Chevrier | |
| | Gilles Créhange | |
| | Alexandra Oudot | |
| | Bertrand Collin | |
| | Alexis Loiseau | |
| | Pattayil Alias Joy | |
| P2860 | cites work | Dispersion of titanate nanotubes for nanomedicine: comparison of PEI and PEG nanohybrids | Q86018490 |
| | Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies | Q26796704 |
| | Concurrent chemoradiation for high-risk prostate cancer | Q26798912 |
| | Roadmap to Clinical Use of Gold Nanoparticles for Radiation Sensitization. | Q30366774 |
| | Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. | Q34227677 |
| | Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer | Q34477201 |
| | Nanoparticles for Radiation Therapy Enhancement: the Key Parameters | Q35824563 |
| | A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902. | Q36480632 |
| | Silica-based nanoparticles for photodynamic therapy applications | Q37774581 |
| | Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial | Q38392753 |
| | Taxane-Grafted Metal-Oxide Nanoparticles as a New Theranostic Tool against Cancer: The Promising Example of Docetaxel-Functionalized Titanate Nanotubes on Prostate Tumors. | Q38703125 |
| | Nanoparticle-based brachytherapy spacers for delivery of localized combined chemoradiation therapy | Q38914849 |
| | The radiosensitization effect of titanate nanotubes as a new tool in radiation therapy for glioblastoma: a proof-of-concept. | Q39155755 |
| | Phase I trial of weekly docetaxel, total androgen blockade, and image-guided intensity-modulated radiotherapy for localized high-risk prostate adenocarcinoma | Q39282443 |
| | Thymidylate synthase expression and activity: relation to S-phase parameters and 5-fluorouracil sensitivity | Q39705491 |
| | Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial | Q40885260 |
| | Sensitivity of a human hybrid cell line (HeLa X skin fibroblast) to radiation-induced neoplastic transformation in G2, M, and mid-G1 phases of the cell cycle | Q41745083 |
| | Concurrent and adjuvant docetaxel with three-dimensional conformal radiation therapy plus androgen deprivation for high-risk prostate cancer: Preliminary results of a multicentre phase II trial | Q42905551 |
| | Multiparametric MRI and post implant CT-based dosimetry after prostate brachytherapy with iodine seeds: The higher the dose to the dominant index lesion, the lower the PSA bounce. | Q52991264 |
| | Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion | Q72209095 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 6357-6364 | |
| P577 | publication date | 2017-08-30 | |
| P1433 | published in | International Journal of Nanomedicine | Q6051502 |
| P1476 | title | Docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model | |
| P478 | volume | 12 | |